Georgetown University Hospital/Lombardi Cancer Center Trials

Georgetown University Hospital/Lombardi Cancer Center	Welcome, Profile Billing Logout

Georgetown University Hospital/Lombardi Cancer Center

Welcome, Profile Billing Logout

4 Trials

6 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cheson, Bruce D

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

ACCRU, NCT02758717: Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

	From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
	Dec 2019 - Dec 2019: From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
	Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019
	Dec 2019 - Dec 2019: Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019

Active, not recruiting

Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

Academic and Community Cancer Research United, National Cancer Institute (NCI)

Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma

08/19

09/24

NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

249

Europe, Canada, US, RoW

Pirtobrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

06/28

12/28

NCT04545333: The clonoSEQ® Watch Registry

Terminated

N/A

465

clonoSEQ Assay

Adaptive Biotechnologies

Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma

10/23

realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting

N/A

100

Tafasitamab

Incyte Corporation, Iqvia Pty Ltd

Diffuse Large B-cell Lymphoma

10/25

08/26

Hwang, Jimmy J

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cheson, Bruce D

Recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

ACCRU, NCT02758717: Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

	From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
	Dec 2019 - Dec 2019: From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
	Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019
	Dec 2019 - Dec 2019: Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019

Active, not recruiting

Academic and Community Cancer Research United, National Cancer Institute (NCI)

08/19

09/24

NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

249

Europe, Canada, US, RoW

Pirtobrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

06/28

12/28

NCT04545333: The clonoSEQ® Watch Registry

Terminated

N/A

465

clonoSEQ Assay

Adaptive Biotechnologies

Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma

10/23

realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting

N/A

100

Tafasitamab

Incyte Corporation, Iqvia Pty Ltd

Diffuse Large B-cell Lymphoma

10/25

08/26

Hwang, Jimmy J

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites